ImClone cements Bristol alliance?
Executive Summary
Former Bristol-Myers Squibb VP-Financial Analysis Michael Howerton named ImClone VP-business development, a newly created position. The two companies recently completed a $2 bil. licensing agreement for ImClone's anticancer agent C225 (1"The Pink Sheet" Sept. 24, p. 20)